<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="57478"><DrugName>gentamicin (topical, CollaRx, ulcer), Innocoll</DrugName><DrugNamesKey><Name id="42931366">Cogenzia</Name><Name id="156330">gentamicin</Name></DrugNamesKey><DrugSynonyms><Name><Value>gentamicin</Value><Types><Type>INN</Type></Types></Name><Name><Value>gentamicin (topical, CollaRx, ulcer), Innocoll</Value></Name><Name><Value>Collatamp G topical</Value></Name><Name><Value>Cogenzia</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>INL-002</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1403-66-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19775">Essex Chemie AG</CompanyOriginator><CompaniesSecondary><Company id="1031557">Innocoll AG</Company><Company id="19775">Essex Chemie AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1031557" type="Company"><TargetEntity id="4297306065" type="organizationId">Innocoll Inc</TargetEntity></SourceEntity><SourceEntity id="19775" type="Company"><TargetEntity id="5000053842" type="organizationId">Merck Sharp &amp; Dohme Research GmbH</TargetEntity></SourceEntity><SourceEntity id="347" type="ciIndication"><TargetEntity id="D014945" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="790" type="ciIndication"><TargetEntity id="10056340" type="MEDDRA"></TargetEntity><TargetEntity id="D017719" type="MeSH"></TargetEntity><TargetEntity id="-1424289263" type="omicsDisease"></TargetEntity><TargetEntity id="495" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="R">Registered</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="347">Wound healing</Indication><Indication id="40">Bacterial infection</Indication><Indication id="790">Diabetic foot ulcer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1541">Aminoglycoside antibiotic</Action><Action id="1594">Antibacterial</Action><Action id="7292">Vulnerary agent</Action><Action id="15186">Topical dermatological antibacterial product</Action></ActionsSecondary><Technologies><Technology id="734">Sponge formulation</Technology><Technology id="66">Antibiotic</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="611">Dermatological formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>J1K</Code><Name>AMINOGLYCOSIDES</Name></Ephmra><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra><Ephmra><Code>D3</Code><Name>WOUND HEALING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-01-15T22:16:08.000Z</LastModificationDate><ChangeDateLast>2017-08-07T00:00:00.000Z</ChangeDateLast><AddedDate>2007-06-07T15:09:51.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1031557" linkType="Company"&gt;Innocoll&lt;/ulink&gt;, under license from &lt;ulink linkID="19775" linkType="Company"&gt;Essex Chemie&lt;/ulink&gt;,  has  developed INL-002 (Cogenzia; Collatamp G topical), a topically applied bioresorbable collagen sponge formulation of   the aminoglycoside antibiotic gentamicin, based on innocoll's CollaRx technology. The product is indicated in markets outside the US and EU for the treatment of    diabetic foot infections (DFI) [&lt;ulink linkID="802850" linkType="Reference"&gt;802850&lt;/ulink&gt;], [&lt;ulink linkID="824732" linkType="Reference"&gt;824732&lt;/ulink&gt;], [&lt;ulink linkID="1115881" linkType="Reference"&gt;1115881&lt;/ulink&gt;], [&lt;ulink linkID="1716219" linkType="Reference"&gt;1716219&lt;/ulink&gt;]. In July 2017, Innocoll was acquired by &lt;ulink linkID="1145978" linkType="Company"&gt;Gurnet Point LP&lt;/ulink&gt; and no further development  of INL-002 was planned [&lt;ulink linkID="1947534" linkType="Reference"&gt;1947534&lt;/ulink&gt;], [&lt;ulink linkID="1947608" linkType="Reference"&gt;1947608&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2014, the drug had been approved for the treatment of DFI in seven countries outside the US and EU, including Canada;  launches and further approvals were expected over the next year    [&lt;ulink linkID="1642823" linkType="Reference"&gt;1642823&lt;/ulink&gt;], [&lt;ulink linkID="1611998" linkType="Reference"&gt;1611998&lt;/ulink&gt;]; however, by February 2016, the product was still not commercially available in any market  [&lt;ulink linkID="1744743" linkType="Reference"&gt;1744743&lt;/ulink&gt;]; in March 2017, this was still the case [&lt;ulink linkID="1909614" linkType="Reference"&gt;1909614&lt;/ulink&gt;]; in July 2017, no further development was planned following Innocoll's acquisition by Gurnet Point LP [&lt;ulink linkID="1947534" linkType="Reference"&gt;1947534&lt;/ulink&gt;], [&lt;ulink linkID="1947608" linkType="Reference"&gt;1947608&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, the phase III COACT efficacy trials were initiated in the US and EU [&lt;ulink linkID="1643361" linkType="Reference"&gt;1643361&lt;/ulink&gt;]; negative topline data were reported in November 2016 [&lt;ulink linkID="1869867" linkType="Reference"&gt;1869867&lt;/ulink&gt;]; in 4Q16, the clinical development programs COAT-1 and -2 were discontinued [&lt;ulink linkID="1909614" linkType="Reference"&gt;1909614&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;INL-002 was previously being developed for other indications, including for the potential treatment of infected or at-risk-of-infection wounds such as venous ulcers, burns and bed sores; in July 2014, phase II trials were planned  [&lt;ulink linkID="1642823" linkType="Reference"&gt;1642823&lt;/ulink&gt;]; however, in 4Q16, Innocoll stopped development of the drug and it is assumed this included any further indications [&lt;ulink linkID="1909614" linkType="Reference"&gt;1909614&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company has also developed and launched an &lt;ulink linkID="57476" linkType="Drug"&gt;implantable formulation of CollaRx gentamicin&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;By July 2014, Innocoll had filed five patent applications in the US, Europe, Canada, Australia and Japan covering methods of use of the drug. If issued, the patents will protect the in the US and Europe to at least 2031  [&lt;ulink linkID="1642823" linkType="Reference"&gt;1642823&lt;/ulink&gt;]. In March 2017, all patent application were in the examination phase [&lt;ulink linkID="1909614" linkType="Reference"&gt;1909614&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 2015, Cogenzia was awarded Qualified Infectious Disease Product (QIDP) designation for the adjunctive treatment of moderate and severe DFI in the US [&lt;ulink linkID="1674394" linkType="Reference"&gt;1674394&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In June 2014, the drug was approved for DFI in Canada   [&lt;ulink linkID="1642823" linkType="Reference"&gt;1642823&lt;/ulink&gt;], [&lt;ulink linkID="1909614" linkType="Reference"&gt;1909614&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;By July 2014, the drug had been approved for DFI in Russia   [&lt;ulink linkID="1642823" linkType="Reference"&gt;1642823&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By November 2014, the drug had received marketing approval for DFI  in Argentina and Mexico [&lt;ulink linkID="1611998" linkType="Reference"&gt;1611998&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By July 2014, the drug had been approved for DFI in Jordan and Saudi Arabia   [&lt;ulink linkID="1642823" linkType="Reference"&gt;1642823&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;South Asia&lt;/subtitle&gt;By November 2014, the drug had been filed for marketing approval for DFI  in India   [&lt;ulink linkID="1611998" linkType="Reference"&gt;1611998&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By November 2014, the drug had been filed for marketing approval for DFI  in Australia   [&lt;ulink linkID="1611998" linkType="Reference"&gt;1611998&lt;/ulink&gt;]; by March 2015, the drug had been approved in Australia [&lt;ulink linkID="1643361" linkType="Reference"&gt;1643361&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Treatment of diabetic foot ulcers&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In May 2015, a randomized, parallel-assignment, double-blind, phase III study (&lt;ulink linkID="229831" linkType="Protocol"&gt;NCT02447172&lt;/ulink&gt;; INN-TOP-005; COACT-2) was initiated in the US to assess the safety and efficacy of Cogenzia in combination with systemic antibiotic therapy in diabetic patients (expected n = 500) with an infected foot. The primary endpoint was the percentage of patients with a clinical cure approximately 10 days after the end of treatment. At that time, the trial was expected to complete in May 2016 [&lt;ulink linkID="1670514" linkType="Reference"&gt;1670514&lt;/ulink&gt;]. In June 2015, the first patient was dosed in the study that was being conducted in both the EU and the US  [&lt;ulink linkID="1670194" linkType="Reference"&gt;1670194&lt;/ulink&gt;]. In June 2016, enrollment was completed [&lt;ulink linkID="1775508" linkType="Reference"&gt;1775508&lt;/ulink&gt;]. In November 2016, topline data were reported. Data demonstrated that both COACT-1 and COACT-2 study did not meet their required primary endpoint of clinical cure of infection after 28 days versus either placebo plus SOC or SOC alone. Data showed drug was tolerated in both studies and had positive clinical response, but did not achieve statistical significance on their shared primary endpoint [&lt;ulink linkID="1869867" linkType="Reference"&gt;1869867&lt;/ulink&gt;]; in 4Q16, the clinical development programs COAT-1 and -2 were discontinued [&lt;ulink linkID="1909614" linkType="Reference"&gt;1909614&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2014, phase III DFI trial protocols had been accepted by the EMA [&lt;ulink linkID="1642823" linkType="Reference"&gt;1642823&lt;/ulink&gt;]. In October 2014, Innocoll requested FDA approval for  improvements to the protocol for the trials and for reconfirmation of the SPA  [&lt;ulink linkID="1611998" linkType="Reference"&gt;1611998&lt;/ulink&gt;]. By March 2015, the   FDA reaffirmed the contents of  SPA and  the two identical phase III efficacy trials were initiated in the US and Europe in patients with moderate to severe DFI. Each trial consists of three arms: Cogenzia, placebo collagen matrix or no collagen matrix; in each arm, Cogenzia would be used as adjuvant therapy in combination with a systemic antibiotic. Patients were to be treated for up to 28 days, with treatment stopped if a patient achieves clinical cure on or after day 14. The primary endpoint was clinical cure at test-of-cure approximately 10 days after the last dose. Planned secondary endpoints include clinical cure time (percentage of patients at each visit), positive clinical response, pathogen eradication time, microbiological outcomes, surgical intervention, or amputation and re-infection. At that time, data from the two phase III trials were expected in 1H16 [&lt;ulink linkID="1643361" linkType="Reference"&gt;1643361&lt;/ulink&gt;]. In April 2015, a double-blind, randomized, placebo-controlled, parallel assignment, phase III study (&lt;ulink linkID="228047" linkType="Protocol"&gt;NCT02427802&lt;/ulink&gt;; INN-TOP-004;COACT-1) was initiated in the US, to assess the safety and efficacy of the drug in combination with systemic antibiotic therapy in diabetic patients (expected n = 500) with   foot ulcers  [&lt;ulink linkID="1660530" linkType="Reference"&gt;1660530&lt;/ulink&gt;]. In May 2015, the first patient was dosed [&lt;ulink linkID="1660531" linkType="Reference"&gt;1660531&lt;/ulink&gt;]. In June 2016, enrollment was completed  [&lt;ulink linkID="1775508" linkType="Reference"&gt;1775508&lt;/ulink&gt;]. In November 2016, negative topline data were reported. Data demonstrated that both COACT-1 and COACT-2 study did not meet their required primary endpoint of clinical cure of infection after 28 days versus either placebo plus SOC or SOC alone. Data showed drug was tolerated in both studies and had positive clinical response, but did not achieve statistical significance on their shared primary endpoint [&lt;ulink linkID="1869867" linkType="Reference"&gt;1869867&lt;/ulink&gt;], [&lt;ulink linkID="1909614" linkType="Reference"&gt;1909614&lt;/ulink&gt;]; in 4Q16, the clinical development programs COAT-1 and -2 were discontinued [&lt;ulink linkID="1909614" linkType="Reference"&gt;1909614&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2010, Innocoll submitted an SPA for a phase III DFI trial to the FDA. The randomized, placebo-controlled, double-blind trial would treat patients with moderate-to-severe infections over 28 days with daily Cogenzia as an adjunct to systemic antibody therapy. The primary endpoint would be the percentage of patients achieving clinical cure at 10-days post-discontinuation of all antibiotic therapy [&lt;ulink linkID="1115881" linkType="Reference"&gt;1115881&lt;/ulink&gt;]. By November 2011, the drug had entered phase III development [&lt;ulink linkID="1239565" linkType="Reference"&gt;1239565&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In April 2008, a second phase II trial (&lt;ulink linkID="10500" linkType="Protocol"&gt;NCT00659646&lt;/ulink&gt;) investigating the product (50 mg gentamycin) when combined with systemic antibiotic therapy for DFI began in the US.  The randomized, parallel, double-blind, placebo-controlled study completed in February 2010 and enrolled 56 patients with moderately infected diabetic foot ulcers. The primary endpoint was percentage of patients with a clinical cure at day 7 [&lt;ulink linkID="897814" linkType="Reference"&gt;897814&lt;/ulink&gt;]. In June 2009,  data from the trial were reported. Efficacy versus the control group was not achieved. However, based on the modified intent-to-treat population, 100% of the patients who received Cogenzia and who completed the trial achieved a clinical cure 2 weeks after completion of treatment, compared to 70% of patients who received systemic antibiotic therapy alone, which was significant. In addition, Cogenzia achieved baseline pathogen eradication of 100% of all microbes present at the wound site for all patients treated and a reduced time to pathogen eradication (both significant) when compared to systemic therapy alone [&lt;ulink linkID="1019081" linkType="Reference"&gt;1019081&lt;/ulink&gt;], [&lt;ulink linkID="1650737" linkType="Reference"&gt;1650737&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, Innocoll  began patient dosing in a DFI phase II trial   (&lt;ulink linkID="49607" linkType="Protocol"&gt;NCT00593567&lt;/ulink&gt;) for diabetic foot ulcers. The multicenter trial would compare Cogenzia to an orally administered antibiotic in the US and UK  [&lt;ulink linkID="861870" linkType="Reference"&gt;861870&lt;/ulink&gt;]. In June 2009,  data from the prospective, randomized trial investigating low-dose Cogenzia (32.5 mg gentamicin) compared with oral &lt;ulink linkID="3492" linkType="Drug"&gt;levofloxacin&lt;/ulink&gt; (750 mg) were reported. A similar number of clinical cures/improvements were seen with Cogenzia as in the levofloxacin group. Pharmacokinetic data demonstrated Cogenzia to have very low systemic concentrations of gentamicin [&lt;ulink linkID="1019081" linkType="Reference"&gt;1019081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, Innocoll filed an IND for DFI  clinically infected or at risk of infection [&lt;ulink linkID="740775" linkType="Reference"&gt;740775&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prevention of diabetic foot ulcers&lt;/subtitle&gt;By February 2015, phase II trials were ongoing for the prevention of DFI [&lt;ulink linkID="1650737" linkType="Reference"&gt;1650737&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, dosing in a phase II trial  (&lt;ulink linkID="10506" linkType="Protocol"&gt;NCT00658957&lt;/ulink&gt;) for the prevention of DFI  began. However, by April 2009, the trial had been terminated as a result of a 'business decision' [&lt;ulink linkID="897988" linkType="Reference"&gt;897988&lt;/ulink&gt;], [&lt;ulink linkID="901013" linkType="Reference"&gt;901013&lt;/ulink&gt;]. In June 2009,  data from the randomized, double-blind study for the prevention of diabetic ulcer infection were reported. Subjects were treated with Cogenzia (32.5 mg gentamicin) twice a week for 4 weeks followed by twice-weekly dosing for 8 weeks. A reduced infection rate of 6% was seen in the Cogenzia arm compared with 36% in the placebo group  [&lt;ulink linkID="1019081" linkType="Reference"&gt;1019081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other wound types&lt;/subtitle&gt;In July 2014, Innocoll planned to conduct phase II trials for treating infected or at-risk-of-infection wounds such as venous ulcers, burns and bed sores [&lt;ulink linkID="1642823" linkType="Reference"&gt;1642823&lt;/ulink&gt;]; however, in 4Q16, Innocoll abandoned development of the drug [&lt;ulink linkID="1909614" linkType="Reference"&gt;1909614&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;After surgical debridement to remove any necrotic tissues, the Cogenzia sponge is applied daily to the DFI and covered with a secondary wound dressing. Cogenzia is highly flexible and will take the shape of the wound bed, minimizing exudate build-up. A high local concentration of gentamicin would penetrate the wound directly, delivering an optimal concentration of drug with minimal systemic absorption. The type-1 collagen in Cogenzia, manufactured using proprietary technologies, is a natural and well-established biocompatible material that can help stimulate the growth of new tissue in the wound bed and accelerate wound healing [&lt;ulink linkID="1650737" linkType="Reference"&gt;1650737&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="347">Wound healing</Indication><StatusDate>2017-03-16T00:00:00.000Z</StatusDate><Source id="1909614" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1909614" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1909614" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2016-09-19T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2015-12-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2009-06-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2016-05-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2009-04-23T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2016-01-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2016-05-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2016-01-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2016-05-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2016-01-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2016-09-19T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2016-05-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2016-01-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2016-01-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2016-05-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2016-05-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2015-12-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031557">Innocoll AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2016-01-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19775">Essex Chemie AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2005-07-01T00:00:00.000Z</StatusDate><Source id="802850" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19775">Essex Chemie AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2005-07-01T00:00:00.000Z</StatusDate><Source id="802850" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2005-07-01T00:00:00.000Z</StatusDate><Source id="802850" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2005-07-01T00:00:00.000Z</StatusDate><Source id="802850" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19775">Essex Chemie AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2005-07-01T00:00:00.000Z</StatusDate><Source id="802850" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2014-11-13T00:00:00.000Z</StatusDate><Source id="1611998" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2014-11-13T00:00:00.000Z</StatusDate><Source id="1611998" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2011-11-15T00:00:00.000Z</StatusDate><Source id="1239565" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2015-03-19T00:00:00.000Z</StatusDate><Source id="1643361" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2007-12-18T00:00:00.000Z</StatusDate><Source id="861870" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2011-11-15T00:00:00.000Z</StatusDate><Source id="1239565" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2007-08-23T00:00:00.000Z</StatusDate><Source id="824732" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate>2014-07-15T00:00:00.000Z</StatusDate><Source id="1642823" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2014-11-13T00:00:00.000Z</StatusDate><Source id="1611998" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2014-11-13T00:00:00.000Z</StatusDate><Source id="1611998" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2014-06-30T00:00:00.000Z</StatusDate><Source id="1909614" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2014-07-15T00:00:00.000Z</StatusDate><Source id="1642823" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2014-07-15T00:00:00.000Z</StatusDate><Source id="1642823" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2014-07-15T00:00:00.000Z</StatusDate><Source id="1642823" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2014-07-15T00:00:00.000Z</StatusDate><Source id="1642823" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2015-03-19T00:00:00.000Z</StatusDate><Source id="1643361" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2014-11-13T00:00:00.000Z</StatusDate><Source id="1611998" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2014-11-13T00:00:00.000Z</StatusDate><Source id="1611998" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2014-07-15T00:00:00.000Z</StatusDate><Source id="1642823" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2014-06-30T00:00:00.000Z</StatusDate><Source id="1909614" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2014-07-15T00:00:00.000Z</StatusDate><Source id="1642823" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2007-12-18T00:00:00.000Z</StatusDate><Source id="861870" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2007-08-23T00:00:00.000Z</StatusDate><Source id="824732" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="IN">India</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2014-11-13T00:00:00.000Z</StatusDate><Source id="1611998" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="IN">India</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2014-11-13T00:00:00.000Z</StatusDate><Source id="1611998" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031557">Innocoll AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2015-03-19T00:00:00.000Z</StatusDate><Source id="1643361" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19775">Essex Chemie AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2005-07-01T00:00:00.000Z</StatusDate><Source id="802850" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="1031557">Innocoll AG</OwnerCompany><Country id="US">US</Country><Indication id="790">Diabetic foot ulcer</Indication><AwardedIndication>Adjunctive treatment of moderate and severe diabetic foot infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-06-30T00:00:00.000Z</MileStoneDate><Source id="1674394" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1107183">EUSA Pharma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1145978">Gurnet Point LP</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O</Smiles></StructureSmiles><Deals><Deal id="109843" title="Innocoll to market Essex Chemie's gentamicin surgical implant   "/><Deal id="110112" title="EUSA to market Innocoll's CollaRx products outside of the US "/><Deal id="248280" title="SERB to acquire EUSA Pharma's critical care business"/></Deals><PatentFamilies><PatentFamily id="1287444" number="WO-00164258" title="Agent For The Treatment Of Wounds"/><PatentFamily id="231680" number="WO-2012139918" title="Methods for treating bacterial infection"/><PatentFamily id="842884" number="WO-00166159" title="Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gurnet Point LP" id="1145978"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>